KOSDAQBiotech & Pharma007390

Naturecell

₩21,400▼ 1.83%2026-11-18 close
Market Cap
₩1.4T
Turnover
₩4.1B
Volume
190K
Shares out.
64.4M
PER
—
PBR
27.3×
EPS
-₩167
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

A wider US path, a heavier funding load

Naturecell says the US approval route for JointStem now leans on its Korean Phase 3 data, but the Q3 2026 operating loss widened to KRW 7.83 billion and a KRW 244.5 billion facility purchase puts funding at the center of the story.

  1. 1

    JointStem: the company said that in a May 2026 FDA meeting, Korean Phase 3 data was indicated as sufficient for a BLA without an additional US Phase 3 trial, but the final review is still ahead.

  2. 2

    Q3 2026 revenue was KRW 2.3 billion, with an operating loss of KRW 7.83 billion and a net loss attributable to controlling shareholders of KRW 9.31 billion (regular report basis).

  3. 3

    Operating losses have been recorded in five consecutive quarters, from Q3 2025 through Q3 2026.

  4. 4

    The company agreed to acquire a Gwacheon production facility for KRW 244.5 billion; the KRW 12.225 billion down payment is scheduled for November 29, 2026, and the balance is due August 31, 2032.

  5. 5

    Earnings-based multiples cannot be calculated because the last four quarters show net losses, and the price-to-book ratio sits in a high premium range relative to net assets.

02

Business structure

Naturecell is a regenerative medicine company built on adult stem cell technology; it was founded in 1971 and adopted its current name in 2013. Its lead pipeline is JointStem, an autologous adipose-derived mesenchymal stem cell therapy given as a single intra-articular injection for severe knee osteoarthritis.

JointStem has been refused marketing approval in Korea several times, and the Ministry of Food and Drug Safety (MFDS) notified another refusal in August 2025. An affiliate resubmitted the application in March 2024 and received the same outcome.

In July 2026 the Seoul Administrative Court ruled in favor of the plaintiff at first instance on one refusal, but the ruling is not final and does not by itself confirm approval. Other pipeline assets include Astrostem for Alzheimer's disease, Bascostem for critical limb ischemia, and Astrostem AU for autism.

The business also spans stem cell culture-medium cosmetics, placental and amniotic stem cell storage, vegan drinks and fermented health foods. The March 2026 IR material listed a placental (amniotic) stem cell storage product as a new 2026 business.

The Naturecell120 consumer ambassador program launched on November 11, 2026, with about 600 members appointed. Segment revenue mix is not part of the regular report figures used here and should be checked in the segment items of future periodic reports. Other Phase 3 programs in osteoarthritis have also drawn press attention.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩3.9B-₩1.4B−35.7%
2025Q4₩6.4B-₩300M−4.1%
2026Q1₩4.1B-₩1.3B−32.6%
2026Q2₩6.2B-₩700M−11.3%
2026Q3₩2.3B-₩7.8B−340.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩21.6B-₩9.5B-₩6.8B−44.1%−11.9%64.5%
2023₩19.4B-₩10.3B-₩11.7B−53.1%−19.0%11.4%
2024₩32.3B₩600M₩1.2B1.8%1.9%11.4%
2025₩20.7B-₩3.6B-₩2.8B−17.6%−4.5%18.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Based on reported results, annual revenue was KRW 216 hundred million in 2022, KRW 194 hundred million in 2023 (down 10.2% year over year), KRW 323 hundred million in 2024 (up 67.1% year over year), and KRW 207 hundred million in 2025 (down 35.9% year over year).

Among 2022–2025, the largest year was 2024 and the smallest was 2023.

The operating loss was KRW 95 hundred million in 2022 and KRW 103 hundred million in 2023, so losses continued (continued losses year over year, with the loss widening), and in 2024 the company turned profitable with an operating profit of KRW 6 hundred million.

The operating margin rose from -44.1% in 2022 and -53.1% in 2023 to 1.8% in 2024. In 2025 the company swung back to an operating loss of KRW 36.5 hundred million, and the operating margin was -17.6%.

Net income attributable to controlling shareholders was a net loss of KRW 68.1 hundred million in 2022 and a net loss of KRW 117 hundred million in 2023, then turned to a profit of KRW 12.3 hundred million in 2024, and turned to a net loss of KRW 28.4 hundred million in 2025.

Net income including non-controlling interests was also reported at the same amounts in the same years. The debt ratio moved from 64.5% in 2022 to 11.4% in 2023, 11.4% in 2024, and 18.6% in 2025.

At the end of 2025, total equity was KRW 630 hundred million, of which equity attributable to controlling shareholders was also KRW 630 hundred million, and total liabilities were KRW 117 hundred million.

Operating cash flow changed from negative to positive, going from -KRW 149 hundred million in 2022 and -KRW 21.3 hundred million in 2023 to KRW 15.1 hundred million in 2024 and KRW 1.6 hundred million in 2025.

On a quarterly basis, revenue was KRW 39 hundred million in Q3 2025, KRW 63.5 hundred million in Q4 2025 (up 62.9% quarter over quarter), KRW 40.6 hundred million in Q1 2026, KRW 62 hundred million in Q2 2026, and KRW 23 hundred million in Q3 2026 (down 41.1% year over year).

The operating loss was KRW 13.9 hundred million in Q3 2025 and KRW 2.6 hundred million in Q4 2025, then grew to KRW 13.2 hundred million in Q1 2026 and KRW 7 hundred million in Q2 2026, and reached KRW 78.3 hundred million in Q3 2026.

In Q4 2025, net income attributable to controlling shareholders turned positive at KRW 3.4 hundred million, but the net loss attributable to controlling shareholders in Q3 2026 was KRW 93.1 hundred million.

The combined net loss attributable to controlling shareholders over the most recent four quarters is KRW 107 hundred million.

05

Industry analysis

Regenerative medicine therapies carry high technology expectations alongside high regulatory risk. In Korea, the MFDS repeatedly refused JointStem approval on the ground that clinical significance was insufficient, which led the company to shift toward a US path.

In the US, JointStem holds both Breakthrough Therapy and RMAT designations, and an expert cited in the press said these may support a request for a priority review. It competes in knee osteoarthritis with other Phase 3 programs.

Larger peers such as Samsung Biologics, Celltrion and SK biopharmaceuticals have commercial products and revenue bases, while Naturecell's annual revenue in the 2022 to 2025 regular reports ranged from KRW 19.4 billion to KRW 32.3 billion, so even within the sector the development stage and revenue structure differ.

For the domestic regenerative medicine industry, the US approval attempt is cited as a test of global validation. The company is also building US production and commercial capacity in parallel, so regulatory talks and manufacturing facilities are linked.

Because regulatory judgments can shift quickly in this field, the FDA's final decision and the outcome of the Korean administrative litigation will set the reference for reading the sector.

06

Outlook

The nearest step the company has described is a pre-BLA meeting with the FDA in the second half of 2026. The company said the FDA is reviewing its chemistry, manufacturing and controls (CMC) data and plans to start the formal filing after the pre-BLA meeting.

CMC readiness is the main variable for the approval timeline. For US production, the company plans to expand capacity at a Baltimore facility in Maryland and to supply initial product from its Korean GMP facility.

In Korea, it is securing a KRW 244.5 billion production facility and clinical center in Gwacheon to expand GMP capacity and build a regenerative medicine clinical center.

The price is payable as a KRW 12.225 billion down payment, a first installment in October 2028, a second installment in October 2031, and the balance on August 31, 2032.

For funding, the March 2026 IR presented a staged plan totaling US$300 million: US$50 million from strategic investors in 2026, US$150 million via a Nasdaq listing in 2027, and US$100 million in 2028.

The Nasdaq listing is being pursued as an ADR Level 3 program, with the plan calling for an application in September to November 2026 and completion in the first half of 2027. Indication expansion is planned for autism and critical limb ischemia.

The company also targets 1,000 Naturecell120 participants by the end of 2026 and 10,000 domestic participants by the end of 2027. These are company targets, and whether they are met should be checked against future regular reports and the approval process.

07

Valuation

PER
—
PBR
27.3×
ROE
-18.7%
EPS
-₩167
BPS
₩807
Dividend per share
₩0

Because the last four quarters show net losses, earnings-based multiples cannot be calculated. Measured against net assets, the price-to-book ratio sits in a high premium range.

Total equity at the end of 2025 was KRW 63 billion, all attributable to controlling shareholders, so the gap between asset value and market value rests on expectations for the business. The dividend yield is below the sector average.

The market value appears to reflect a large expectation for the JointStem US approval and the planned Nasdaq listing. If the approval timeline slips or funding is not raised at the planned scale, these assumptions could change.

Conversely, progress in the approval process and the build-out of production capacity could change the earnings structure. The valuation therefore depends more on pipeline progress and funding outcomes than on current earnings metrics.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

A changed US approval route

The company said that at a May 2026 FDA meeting, the FDA indicated Korean Phase 3 data could support a BLA without an additional US Phase 3 trial or accelerated approval. This raised expectations for shorter timelines and lower costs than the dual-track plan presented in March 2026.

The company said this route could reduce development time by several years and costs by hundreds of billions of won.

Regulatory designations and indication expansion

JointStem holds both the FDA Breakthrough Therapy designation and RMAT designation. Press coverage cited an expert saying these may support a request for a priority review, which can shorten review timing. The company is also developing autism and critical limb ischemia as additional indications.

First-instance win in the Korean lawsuit

In July 2026 the Seoul Administrative Court ruled in favor of the plaintiff in a suit seeking to cancel an MFDS refusal of the JointStem marketing approval. The company disclosed the ruling voluntarily. The decision is a first-instance ruling, not final, and does not by itself confirm the product approval.

09

Bear factors

Wider losses in the latest quarter

Q3 2026 revenue was KRW 2.3 billion, down 62.9% from the prior quarter, while the operating loss widened to KRW 7.83 billion and the net loss attributable to controlling shareholders to KRW 9.31 billion. Operating losses have been recorded in five consecutive quarters since Q3 2025. The 2025 annual operating loss of KRW 3.65 billion also returned the company to a loss.

Funding needs and financing burden

The Gwacheon facility carries a KRW 244.5 billion purchase price, with a KRW 12.225 billion down payment followed by a balance of KRW 195.6 billion at the current price, due by August 31, 2032.

Operating cash flow was an outflow of about KRW 4 billion in the first half of 2026 per the semi-annual report, and a KRW 17 billion convertible bond was issued in August 2026. Whether the staged US$300 million funding plan is executed as planned is the key question.

Approval uncertainty in Korea and the US

In Korea, JointStem's conditional approval application in 2018 and its formal application in 2021 were both refused, and a 2024 resubmission had the same result. Another refusal was notified in August 2025, and the first-instance win is not final.

On the US path, the FDA position is as described by the company, and CMC readiness is seen as the largest variable.

10

Risk factors

Regulatory and approval risk

There is no assurance that the BLA filing and FDA review will proceed on the company's schedule. The FDA's final judgment may differ from the company's description, and the pre-BLA timing could shift with the CMC review. Given the Korean refusal history, administrative procedures could also take longer. Approval depends on two axes: the interpretation of clinical data and manufacturing quality.

Funding and dilution risk

Balance payments for the Gwacheon facility, US production investment and clinical costs overlap, so reliance on external funding is high. A KRW 17 billion convertible bond was issued in August 2026, and the Nasdaq ADR listing was reported to be in discussions with investment banks.

Depending on the financing structure, existing shareholders could face dilution. Operating cash flow was an outflow in the first half of 2026.

Earnings volatility and execution risk

Quarterly revenue ranged widely, from KRW 3.9 billion in Q3 2025 to KRW 6.35 billion in Q4 2025, KRW 4.06 billion in Q1 2026, KRW 6.2 billion in Q2 2026 and KRW 2.3 billion in Q3 2026, which limits predictability.

Product mix now spans cosmetics, storage and health foods alongside therapeutics, which makes profitability by business hard to separate. Whether the Naturecell120 participant targets are met could also affect revenue.

11

What to watch next

  1. November 29, 2026

    Scheduled payment date for the KRW 12.225 billion down payment on the Gwacheon production facility. Whether the payment proceeds as scheduled is the first check point for the cash flow of this large facility investment.

  2. Second half of 2026

    Timing of the pre-BLA meeting with the FDA. Whether the FDA's comments on the CMC data become clear at this meeting will set the reference for the BLA filing timeline.

  3. End of November 2026

    The final month of the Nasdaq ADR listing application window (September to November 2026) the company presented. Whether a listing application is disclosed and whether a lead investment bank is named are the points to check.

  4. December 31, 2026

    Target date for 1,000 Naturecell120 participants. How far the expansion feeds into sales will be visible in the sales-related items of later annual reports.

  5. March 31, 2027

    Statutory filing deadline for the 2026 annual report, the next regular report. The full-year 2026 operating results, cash flow and funding structure for the Gwacheon facility will first be consolidated in this report.

12

Overall view

Naturecell says the US path for JointStem has widened around Korean Phase 3 data, while its regular-report results show a continuing loss pattern.

The 2024 operating profit turnaround and the Q4 2025 profit attributable to controlling shareholders are real, but the 2025 annual operating loss of KRW 3.65 billion and the Q3 2026 operating loss of KRW 7.83 billion better represent the recent trend.

Positive factors include the FDA designations, the widening approval route, indication expansion and the first-instance court win in Korea. Negative factors include the widening quarterly loss, the funding burden from the KRW 244.5 billion facility, and the Korean refusal history with approval uncertainty.

Strengths and weaknesses are both material, and current market value appears to rest more on pipeline progress than on earnings. The next checkpoints are the pre-BLA meeting outcome in the second half of 2026, the down payment on November 29, 2026, and whether a Nasdaq listing application is filed.

The 2026 annual report will first consolidate full-year operating results and cash flow, making the cash flow structure at that point an important reference. This report does not offer an investment opinion or a target price.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. hankyung.com
  2. news.mtn.co.kr
  3. news.mtn.co.kr
  4. kukinews.com
  5. kor.theasian.asia
  6. newstown.co.kr
  7. thefirstmedia.net
  8. stemcellinkorea.com
  9. kind.krx.co.kr
  10. news.nate.com
  11. news.nate.com
  12. biotimes.co.kr
  13. kor.theasian.asia
  14. hitnews.co.kr
  15. newspim.com
  16. yakup.com
  17. fntimes.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis